How to pronounce "wavered"

[Music]

[Music]

[Music] [Applause]

what better way to

what better way to

what better way to start this is my son Charlie he's 11

start this is my son Charlie he's 11

start this is my son Charlie he's 11 years

years

years old and he's an hysterical quirky kid

old and he's an hysterical quirky kid

old and he's an hysterical quirky kid he loves life and he proudly marches to

he loves life and he proudly marches to

he loves life and he proudly marches to the beat of his own

the beat of his own

the beat of his own drum he loves Kobe Bryant and Dr dre as

drum he loves Kobe Bryant and Dr dre as

drum he loves Kobe Bryant and Dr dre as much as he loves writing risque mad libs

much as he loves writing risque mad libs

much as he loves writing risque mad libs or preparing brisket paninis on his own

or preparing brisket paninis on his own

or preparing brisket paninis on his own George Foreman girl

however when Charlie was three and a

however when Charlie was three and a

however when Charlie was three and a half years old the dark fell from the

half years old the dark fell from the

half years old the dark fell from the sky landed on my family and broke it

sky landed on my family and broke it

sky landed on my family and broke it into more pieces than could ever be

into more pieces than could ever be

into more pieces than could ever be imagined so many pieces in fact that

imagined so many pieces in fact that

imagined so many pieces in fact that life as we knew it was

life as we knew it was

life as we knew it was over you see my son Charlie was

over you see my son Charlie was

over you see my son Charlie was diagnosed with duchen muscular distrophe

diagnosed with duchen muscular distrophe

diagnosed with duchen muscular distrophe the most common and the most aggressive

the most common and the most aggressive

the most common and the most aggressive form of duchen mus of

form of duchen mus of

form of duchen mus of musculardrophe it's an infamous disease

musculardrophe it's an infamous disease

musculardrophe it's an infamous disease in that it's the number one genetic

in that it's the number one genetic

in that it's the number one genetic killer in the world of

killer in the world of

killer in the world of children children that suffer from

children children that suffer from

children children that suffer from duchen musculardrophe are missing a

duchen musculardrophe are missing a

duchen musculardrophe are missing a protein in their body called distroofen

protein in their body called distroofen

protein in their body called distroofen which is the largest protein in the body

which is the largest protein in the body

which is the largest protein in the body and it's essential for muscle strength

and it's essential for muscle strength

and it's essential for muscle strength and function an analogy that I often use

and function an analogy that I often use

and function an analogy that I often use is it's like the steel cables of a

is it's like the steel cables of a

is it's like the steel cables of a suspension bridge without the steel

suspension bridge without the steel

suspension bridge without the steel cables the bridge is unable to withstand

cables the bridge is unable to withstand

cables the bridge is unable to withstand any of mother nature's stresses kids

any of mother nature's stresses kids

any of mother nature's stresses kids that are missing this very important

that are missing this very important

that are missing this very important protein the muscles begin to deteriorate

protein the muscles begin to deteriorate

protein the muscles begin to deteriorate even with simple activities as getting

even with simple activities as getting

even with simple activities as getting up walking jumping uh for instance it

up walking jumping uh for instance it

up walking jumping uh for instance it affects one in every 3,500

affects one in every 3,500

affects one in every 3,500 boys it's an equal opportunity disease

boys it's an equal opportunity disease

boys it's an equal opportunity disease in that it knows no ethnic or geographic

in that it knows no ethnic or geographic

in that it knows no ethnic or geographic boundaries doesn't matter what country

boundaries doesn't matter what country

boundaries doesn't matter what country you're from doesn't matter what color

you're from doesn't matter what color

you're from doesn't matter what color your skin is one in every 3,500 boys

your skin is one in every 3,500 boys

your skin is one in every 3,500 boys throughout the world is born with this

throughout the world is born with this

throughout the world is born with this disease the prognosis is horrifying it's

disease the prognosis is horrifying it's

disease the prognosis is horrifying it's 100%

100%

100% fatal the disease is rapidly progressive

fatal the disease is rapidly progressive

fatal the disease is rapidly progressive and affects every muscle in a kid's body

and affects every muscle in a kid's body

and affects every muscle in a kid's body the their skeletal muscles the heart

the their skeletal muscles the heart

the their skeletal muscles the heart which is a muscle and the muscles of

which is a muscle and the muscles of

which is a muscle and the muscles of respiration

respiration

respiration by adolescence the kids are wheelchair

by adolescence the kids are wheelchair

by adolescence the kids are wheelchair bound and by their mid to late 20s they

bound and by their mid to late 20s they

bound and by their mid to late 20s they die this is the type of news that

die this is the type of news that

die this is the type of news that paralyzes

paralyzes

paralyzes most the sadness the anger and the fear

most the sadness the anger and the fear

most the sadness the anger and the fear is enough to stop anyone in their tracks

is enough to stop anyone in their tracks

is enough to stop anyone in their tracks for my wife and I we were determined to

for my wife and I we were determined to

for my wife and I we were determined to push through

this and to save our son's

this and to save our son's

this and to save our son's life in just four months after we

life in just four months after we

life in just four months after we received the tragic news that our son

received the tragic news that our son

received the tragic news that our son was diagnosed with duchen musculardrophe

was diagnosed with duchen musculardrophe

was diagnosed with duchen musculardrophe we decided to start Charlie's Fund a

we decided to start Charlie's Fund a

we decided to start Charlie's Fund a nonprofit

nonprofit

nonprofit organization that invests in

organization that invests in

organization that invests in therapeutics

therapeutics

therapeutics development for a therapy or a cure for

development for a therapy or a cure for

development for a therapy or a cure for duchen

duchen

duchen musculardrophe our mission is simple and

musculardrophe our mission is simple and

musculardrophe our mission is simple and crucial and we have never wavered from

crucial and we have never wavered from

crucial and we have never wavered from it from the first day we started our

it from the first day we started our

it from the first day we started our foundation we raise money and we direct

foundation we raise money and we direct

foundation we raise money and we direct it into the hands of those that we feel

it into the hands of those that we feel

it into the hands of those that we feel have the best shot on goal developing a

have the best shot on goal developing a

have the best shot on goal developing a therapy or a cure in time to save my son

therapy or a cure in time to save my son

therapy or a cure in time to save my son Charlie's life and the tens of thousands

Charlie's life and the tens of thousands

Charlie's life and the tens of thousands of boys who are needlessly suffering

of boys who are needlessly suffering

of boys who are needlessly suffering from this disease just like

him we are in a race against time my

him we are in a race against time my

him we are in a race against time my wife and I have been acutely aware of

wife and I have been acutely aware of

wife and I have been acutely aware of this fact since day one and

this fact since day one and

this fact since day one and unfortunately DMD was

unfortunately DMD was

unfortunately DMD was winning and progress was simply not

winning and progress was simply not

winning and progress was simply not moving fast enough for

moving fast enough for

moving fast enough for us there were no drugs and there

us there were no drugs and there

us there were no drugs and there currently are no drugs available for

currently are no drugs available for

currently are no drugs available for these kids to take in order to slow the

these kids to take in order to slow the

these kids to take in order to slow the progress of the disease with the

progress of the disease with the

progress of the disease with the exception of steroids which does very

exception of steroids which does very

exception of steroids which does very little to slow the

little to slow the

little to slow the devastation and worse it's associated

devastation and worse it's associated

devastation and worse it's associated with a host of terrible terrible side

with a host of terrible terrible side

with a host of terrible terrible side effects so bad in fact that many

effects so bad in fact that many

effects so bad in fact that many children are simply not able to take the

children are simply not able to take the

children are simply not able to take the drug

itself we knew we had to do things

itself we knew we had to do things

itself we knew we had to do things differently and we had to act

differently and we had to act

differently and we had to act quickly one thing that was very apparent

quickly one thing that was very apparent

quickly one thing that was very apparent to me was that we needed appropriate

to me was that we needed appropriate

to me was that we needed appropriate level of focus to be devoted towards

level of focus to be devoted towards

level of focus to be devoted towards this problem in order to make a

this problem in order to make a

this problem in order to make a difference in time for Charlie at the

difference in time for Charlie at the

difference in time for Charlie at the time we hired the world's only PhD level

time we hired the world's only PhD level

time we hired the world's only PhD level uh scientist who devoted a 100% of his

uh scientist who devoted a 100% of his

uh scientist who devoted a 100% of his efforts every single waking moment to

efforts every single waking moment to

efforts every single waking moment to help us realize a therapy or a cure for

help us realize a therapy or a cure for

help us realize a therapy or a cure for these boys it's amazing to think of

these boys it's amazing to think of

these boys it's amazing to think of something so simple as just devoting

something so simple as just devoting

something so simple as just devoting enough attention to a disease is what's

enough attention to a disease is what's

enough attention to a disease is what's needed and yet no one had done it before

needed and yet no one had done it before

needed and yet no one had done it before we did

we did

we did it another thing that was acutely that

it another thing that was acutely that

it another thing that was acutely that my wife and I were acutely aware of from

my wife and I were acutely aware of from

my wife and I were acutely aware of from the beginning was a sense of urgency

the beginning was a sense of urgency

the beginning was a sense of urgency time was not on our side the window of

time was not on our side the window of

time was not on our side the window of opportunity was

opportunity was

opportunity was narrow one of the annual meetings that

narrow one of the annual meetings that

narrow one of the annual meetings that my wife and I and all the key opinion

my wife and I and all the key opinion

my wife and I and all the key opinion leaders in the field for duchen

leaders in the field for duchen

leaders in the field for duchen musculardrophe

musculardrophe

musculardrophe uh one scientist uh was speaking and his

uh one scientist uh was speaking and his

uh one scientist uh was speaking and his words have always stuck with me he got

words have always stuck with me he got

words have always stuck with me he got up there and he spoke to an audience of

up there and he spoke to an audience of

up there and he spoke to an audience of several hundred people and he

several hundred people and he

several hundred people and he said "Myself included there are many

said "Myself included there are many

said "Myself included there are many scientists in this room who can cure

scientists in this room who can cure

scientists in this room who can cure duchen musculardrophe in a mouse it's

duchen musculardrophe in a mouse it's

duchen musculardrophe in a mouse it's time we move these drugs out of the

time we move these drugs out of the

time we move these drugs out of the animal models and into the kids before

animal models and into the kids before

animal models and into the kids before another generation is needlessly lost."

another generation is needlessly lost."

another generation is needlessly lost." I never forgot those words

I never forgot those words

I never forgot those words that evening when I came home I said to

that evening when I came home I said to

that evening when I came home I said to my wife I have an idea of what we're

my wife I have an idea of what we're

my wife I have an idea of what we're going to

going to

going to do we're going to screen every FDA

do we're going to screen every FDA

do we're going to screen every FDA approved drug in the country for other

approved drug in the country for other

approved drug in the country for other diseases and we're going to develop

diseases and we're going to develop

diseases and we're going to develop tests to see if there's any of these

tests to see if there's any of these

tests to see if there's any of these drugs that have any benefit in duchen

drugs that have any benefit in duchen

drugs that have any benefit in duchen musculardrophe so we developed these

musculardrophe so we developed these

musculardrophe so we developed these assays which are tests that are used to

assays which are tests that are used to

assays which are tests that are used to screen uh thousands tens of thousands

screen uh thousands tens of thousands

screen uh thousands tens of thousands sometimes millions of drugs in this case

sometimes millions of drugs in this case

sometimes millions of drugs in this case there was a finite number of drugs

there was a finite number of drugs

there was a finite number of drugs there's approximately 4,000 FDA approved

there's approximately 4,000 FDA approved

there's approximately 4,000 FDA approved drugs for other

drugs for other

drugs for other diseases just as I expected we got very

diseases just as I expected we got very

diseases just as I expected we got very promising hits from that screen and then

promising hits from that screen and then

promising hits from that screen and then we tested them in the animal model for

we tested them in the animal model for

we tested them in the animal model for this disease some of which showed great

this disease some of which showed great

this disease some of which showed great promise the results of this innovative

promise the results of this innovative

promise the results of this innovative initiative two clinical trials one of

initiative two clinical trials one of

initiative two clinical trials one of which is currently taking place at

which is currently taking place at

which is currently taking place at John's Hopkins University the other is

John's Hopkins University the other is

John's Hopkins University the other is taking place at Cincinnati Children's

taking place at Cincinnati Children's

taking place at Cincinnati Children's Hospital both of which are working on

Hospital both of which are working on

Hospital both of which are working on drugs that offer great promise in

drugs that offer great promise in

drugs that offer great promise in improving the strength and function of

improving the strength and function of

improving the strength and function of the skeletal muscles and the hearts of

the skeletal muscles and the hearts of

the skeletal muscles and the hearts of these kids which means that there is

these kids which means that there is

these kids which means that there is a good possibility that the quantity and

a good possibility that the quantity and

a good possibility that the quantity and quality of these children's lives for

quality of these children's lives for

quality of these children's lives for the first time in the history of this

the first time in the history of this

the first time in the history of this disease is going to be marketkedly

disease is going to be marketkedly

disease is going to be marketkedly improved

something else that we wanted to do that

something else that we wanted to do that

something else that we wanted to do that was needed and that would distinguish

was needed and that would distinguish

was needed and that would distinguish ourselves from the rest of the uh people

ourselves from the rest of the uh people

ourselves from the rest of the uh people and experts that were devoted to doing

and experts that were devoted to doing

and experts that were devoted to doing something about this disease was taking

something about this disease was taking

something about this disease was taking risks thinking outside the box being

risks thinking outside the box being

risks thinking outside the box being innovative in the early few months after

innovative in the early few months after

innovative in the early few months after we started Charlie's fund I would

we started Charlie's fund I would

we started Charlie's fund I would frantically scour the internet looking

frantically scour the internet looking

frantically scour the internet looking for all of the most promising research

for all of the most promising research

for all of the most promising research research that existed on this disease i

research that existed on this disease i

research that existed on this disease i picked up the phone and I called every

picked up the phone and I called every

picked up the phone and I called every scientist every clinician and every CEO

scientist every clinician and every CEO

scientist every clinician and every CEO of a biotech company that was doing

of a biotech company that was doing

of a biotech company that was doing anything that had to do with this

anything that had to do with this

anything that had to do with this disease

disease

disease within months I came up with a game plan

within months I came up with a game plan

within months I came up with a game plan with the help of uh my adviserss what we

with the help of uh my adviserss what we

with the help of uh my adviserss what we needed to do in this mining through the

needed to do in this mining through the

needed to do in this mining through the uh uh multitude of possibilities i came

uh uh multitude of possibilities i came

uh uh multitude of possibilities i came across this seedstage biotech company in

across this seedstage biotech company in

across this seedstage biotech company in the

the

the Netherlands they had less than 30 people

Netherlands they had less than 30 people

Netherlands they had less than 30 people at the time and they were working on

at the time and they were working on

at the time and they were working on proprietary technology that is something

proprietary technology that is something

proprietary technology that is something from Star Trek it's a type of modified

from Star Trek it's a type of modified

from Star Trek it's a type of modified gene therapy that tricks the muscles

gene therapy that tricks the muscles

gene therapy that tricks the muscles into once again making the missing

into once again making the missing

into once again making the missing protein I spoke of earlier called

protein I spoke of earlier called

protein I spoke of earlier called distroofen although making it in a

distroofen although making it in a

distroofen although making it in a shortened form with the hope that maybe

shortened form with the hope that maybe

shortened form with the hope that maybe there's still enough function in this

there's still enough function in this

there's still enough function in this protein that the kids quality of life

protein that the kids quality of life

protein that the kids quality of life that the the speed at which this uh

that the the speed at which this uh

that the the speed at which this uh muscle destruction was taking place

muscle destruction was taking place

muscle destruction was taking place would slow

down we also did something that was out

down we also did something that was out

down we also did something that was out of the box and innovative most

of the box and innovative most

of the box and innovative most nonprofits when they're providing funds

nonprofits when they're providing funds

nonprofits when they're providing funds or support for research do so in the

or support for research do so in the

or support for research do so in the form of a gift or sponsored research

form of a gift or sponsored research

form of a gift or sponsored research agreement where they roll out their

agreement where they roll out their

agreement where they roll out their funding incrementally with milestone

funding incrementally with milestone

funding incrementally with milestone achievement we decided to do something

achievement we decided to do something

achievement we decided to do something bigger knowing that drug development is

bigger knowing that drug development is

bigger knowing that drug development is expensive if these guys were on to

expensive if these guys were on to

expensive if these guys were on to something exciting they were going to

something exciting they were going to

something exciting they were going to need the money to demonstrate the proof

need the money to demonstrate the proof

need the money to demonstrate the proof of concept so that enough value could be

of concept so that enough value could be

of concept so that enough value could be built into this company that it would

built into this company that it would

built into this company that it would turn the attention of big biotech and

turn the attention of big biotech and

turn the attention of big biotech and big pharma the entities that have the

big pharma the entities that have the

big pharma the entities that have the sufficient funds to take this promising

sufficient funds to take this promising

sufficient funds to take this promising drug over the finish line we made an

drug over the finish line we made an

drug over the finish line we made an equity investment of

equity investment of

equity investment of $650,000 into this company the first

$650,000 into this company the first

$650,000 into this company the first $650,000 we raised went into this

$650,000 we raised went into this

$650,000 we raised went into this company

company

company the result they're in a phase three

the result they're in a phase three

the result they're in a phase three clinical trial in Europe in the United

clinical trial in Europe in the United

clinical trial in Europe in the United States in Canada and Asia and currently

States in Canada and Asia and currently

States in Canada and Asia and currently it is the most promising therapy in the

it is the most promising therapy in the

it is the most promising therapy in the world for duchen musculardrophe

world for duchen musculardrophe

world for duchen musculardrophe because of our support and others who

because of our support and others who

because of our support and others who were willing to take a risk in this

were willing to take a risk in this

were willing to take a risk in this company they have now recently uh

company they have now recently uh

company they have now recently uh partnered with Glacos Smith Klein the

partnered with Glacos Smith Klein the

partnered with Glacos Smith Klein the world's biggest pharmaceutical company

world's biggest pharmaceutical company

world's biggest pharmaceutical company in the world for a deal potentially

in the world for a deal potentially

in the world for a deal potentially worth over

worth over

worth over $720

$720

$720 million with upfronts and milestone

million with upfronts and milestone

million with upfronts and milestone achievements it's amazing what taking a

achievements it's amazing what taking a

achievements it's amazing what taking a risk an educated risk if you will can

risk an educated risk if you will can

risk an educated risk if you will can turn out if this company continues to be

turn out if this company continues to be

turn out if this company continues to be successful then Charlie's fund will be

successful then Charlie's fund will be

successful then Charlie's fund will be successful because of our equity

successful because of our equity

successful because of our equity investment the return on our investment

investment the return on our investment

investment the return on our investment will be used to refuel our efforts in

will be used to refuel our efforts in

will be used to refuel our efforts in other promising therapeutic strategies

other promising therapeutic strategies

other promising therapeutic strategies and I can once again place another

and I can once again place another

and I can once again place another educated bet hopefully on the next uh

educated bet hopefully on the next uh

educated bet hopefully on the next uh biotech company working on something for

biotech company working on something for

biotech company working on something for our

our

our children in summary our unprecedented

children in summary our unprecedented

children in summary our unprecedented progress in a short time had less to do

progress in a short time had less to do

progress in a short time had less to do about this groundbreaking scientific

about this groundbreaking scientific

about this groundbreaking scientific discovery and more to do with having the

discovery and more to do with having the

discovery and more to do with having the confidence and willingness to think

confidence and willingness to think

confidence and willingness to think outside the box

outside the box

outside the box on November

on November

on November 11th

11th

11th 1111 my son turned

11 this apicious numerological

11 this apicious numerological

11 this apicious numerological phenomenon occurs literally once every

phenomenon occurs literally once every

phenomenon occurs literally once every 10,000

10,000

10,000 years it's amazing i remember on

years it's amazing i remember on

years it's amazing i remember on Charlie's birthday I looked at my wife

Charlie's birthday I looked at my wife

Charlie's birthday I looked at my wife Tracy and I said to her "This is the

Tracy and I said to her "This is the

Tracy and I said to her "This is the year I'm going to deliver a devastating

year I'm going to deliver a devastating

year I'm going to deliver a devastating blow to DMD." And I want to look back at

blow to DMD." And I want to look back at

blow to DMD." And I want to look back at this year with no

this year with no

this year with no regrets it's easy to lose focus when

regrets it's easy to lose focus when

regrets it's easy to lose focus when you're doing something like we're trying

you're doing something like we're trying

you're doing something like we're trying to accomplish at Charlie's Fun there's

to accomplish at Charlie's Fun there's

to accomplish at Charlie's Fun there's so much at stake there are so many

so much at stake there are so many

so much at stake there are so many possibilities there's no room for

possibilities there's no room for

possibilities there's no room for error but moments like this are

error but moments like this are

error but moments like this are important and it always goes back to our

important and it always goes back to our

important and it always goes back to our mission and the one question are we

mission and the one question are we

mission and the one question are we doing everything we can to move things

doing everything we can to move things

doing everything we can to move things as fast as

as fast as

as fast as possible halo

possible halo

possible halo fugenone was a promising drug that I

fugenone was a promising drug that I

fugenone was a promising drug that I remember reading in a respected

remember reading in a respected

remember reading in a respected scientific journal that was being tested

scientific journal that was being tested

scientific journal that was being tested in the animal model for duchen

in the animal model for duchen

in the animal model for duchen musculardrophe a drug that was known to

musculardrophe a drug that was known to

musculardrophe a drug that was known to venture capitalists and scientists for

venture capitalists and scientists for

venture capitalists and scientists for other diseases that involved abnormal

other diseases that involved abnormal

other diseases that involved abnormal fibrosis but the venture capitalists

fibrosis but the venture capitalists

fibrosis but the venture capitalists lost faith after spending $80 million in

lost faith after spending $80 million in

lost faith after spending $80 million in this drug but I knew that there was

this drug but I knew that there was

this drug but I knew that there was still great promise in this drug for

still great promise in this drug for

still great promise in this drug for duchen musculardrophe after speaking

duchen musculardrophe after speaking

duchen musculardrophe after speaking with our scientific adviserss

with our scientific adviserss

with our scientific adviserss the problem was I didn't have the tools

the problem was I didn't have the tools

the problem was I didn't have the tools to figure out how to get the drug and

to figure out how to get the drug and

to figure out how to get the drug and how to push it forward so that it could

how to push it forward so that it could

how to push it forward so that it could potentially be given as a medicine to my

potentially be given as a medicine to my

potentially be given as a medicine to my son and kids like

son and kids like

son and kids like him i didn't turn my turn away from this

him i didn't turn my turn away from this

him i didn't turn my turn away from this opportunity instead we once again

opportunity instead we once again

opportunity instead we once again thought outside the box we decided to

thought outside the box we decided to

thought outside the box we decided to recruit a team of drug development

recruit a team of drug development

recruit a team of drug development experts people that represented the best

experts people that represented the best

experts people that represented the best and brightest in big pharma and

and brightest in big pharma and

and brightest in big pharma and biotech individuals with decades of

biotech individuals with decades of

biotech individuals with decades of experience in making drugs

experience in making drugs

experience in making drugs we did this in order to help us

we did this in order to help us

we did this in order to help us negotiate deals with the biotech

negotiate deals with the biotech

negotiate deals with the biotech companies to help us establish clinical

companies to help us establish clinical

companies to help us establish clinical trial networks with the key opinion

trial networks with the key opinion

trial networks with the key opinion leaders and the medical institutions

leaders and the medical institutions

leaders and the medical institutions that would be conducting the trials and

that would be conducting the trials and

that would be conducting the trials and to help us communicate with the

to help us communicate with the

to help us communicate with the regulatory authorities which is

regulatory authorities which is

regulatory authorities which is essential like the FDA in the United

essential like the FDA in the United

essential like the FDA in the United States and the EMEA which is the

States and the EMEA which is the

States and the EMEA which is the equivalent regulatory body in Europe

equivalent regulatory body in Europe

equivalent regulatory body in Europe incredibly in less than one year what

incredibly in less than one year what

incredibly in less than one year what have we accomplished with this team we

have we accomplished with this team we

have we accomplished with this team we acquired that promising drug from that

acquired that promising drug from that

acquired that promising drug from that dormant Israeli company and we started

dormant Israeli company and we started

dormant Israeli company and we started believe it or not our own biotech

believe it or not our own biotech

believe it or not our own biotech company called Halo Therapeutics in

company called Halo Therapeutics in

company called Halo Therapeutics in order to accelerate the development of

order to accelerate the development of

order to accelerate the development of this promising drug that we now call HT

this promising drug that we now call HT

this promising drug that we now call HT 100 and best of all we are on track and

100 and best of all we are on track and

100 and best of all we are on track and expect to begin a clinical trial this

expect to begin a clinical trial this

expect to begin a clinical trial this year

year

year as a result of the great promise of this

as a result of the great promise of this

as a result of the great promise of this drug and the expertise of the team that

drug and the expertise of the team that

drug and the expertise of the team that I

I

I assembled recently the United States and

assembled recently the United States and

assembled recently the United States and the European Union has granted Halo

the European Union has granted Halo

the European Union has granted Halo Therapeutics orphan drug

Therapeutics orphan drug

Therapeutics orphan drug status this distinction provides us with

status this distinction provides us with

status this distinction provides us with the regulatory and financial incentives

the regulatory and financial incentives

the regulatory and financial incentives to significantly compress the time and

to significantly compress the time and

to significantly compress the time and cost to get drugs into clinical trial

cost to get drugs into clinical trial

cost to get drugs into clinical trial and the marketplace again focusing on

and the marketplace again focusing on

and the marketplace again focusing on the

the

the urgency because of our bold

urgency because of our bold

urgency because of our bold efforts and the willingness and courage

efforts and the willingness and courage

efforts and the willingness and courage to take matters into our own hands we

to take matters into our own hands we

to take matters into our own hands we have now attracted the attention of the

have now attracted the attention of the

have now attracted the attention of the biotech

biotech

biotech industry in fact the Wall Street Journal

industry in fact the Wall Street Journal

industry in fact the Wall Street Journal has recently written an article about

has recently written an article about

has recently written an article about the groundbreaking innovation of

the groundbreaking innovation of

the groundbreaking innovation of Charlie's fund and halo therapeutics in

Charlie's fund and halo therapeutics in

Charlie's fund and halo therapeutics in the world of drug development and orphan

the world of drug development and orphan

the world of drug development and orphan diseases

i'm a Harvard trained physician who has

i'm a Harvard trained physician who has

i'm a Harvard trained physician who has an intimate understanding of the

an intimate understanding of the

an intimate understanding of the language of genetic

language of genetic

language of genetic medicine but my medical degree had

medicine but my medical degree had

medicine but my medical degree had nothing to do with getting us to the

nothing to do with getting us to the

nothing to do with getting us to the point of where we are right

point of where we are right

point of where we are right now instead it's been focus relentless

now instead it's been focus relentless

now instead it's been focus relentless determination and the courage to

determination and the courage to

determination and the courage to innovate

although for us the motivation was the

although for us the motivation was the

although for us the motivation was the need to save my son's life in

need to save my son's life in

need to save my son's life in reality these principles can be applied

reality these principles can be applied

reality these principles can be applied to any challenge that seemed to be

to any challenge that seemed to be

to any challenge that seemed to be insurmountable and it's these same

insurmountable and it's these same

insurmountable and it's these same principles that will help us rewrite the

principles that will help us rewrite the

principles that will help us rewrite the medical textbooks for this murderous

medical textbooks for this murderous

medical textbooks for this murderous disease and help us finally make duchen

disease and help us finally make duchen

disease and help us finally make duchen history thank you

history thank you

history thank you [Applause]